https://www.statnews.com/2020/04/23/data-on-gileads-remdesivir-released-by-accident-show-no-benefit-for-coronavirus-patients/　

https://www.cnbc.com/2020/04/23/gilead-says-draft-of-coronavirus-treatment-results-contain-inappropriate-characterization-and-are-inconclusive.html

According to the summary of the China study, remdesivir was “not associated with a difference in time to clinical improvement” compared to a standard of care control. After one month, it appeared 13.9% of the remdesivir patients had died compared to 12.8% of patients in the control arm. The difference was not statistically significant.